Recommendations on clinical proof of efficacy for potential scar prevention and reduction therapies

James A. Bush, D. Angus McGrouther, V. Leroy Young, David Herndon, Michael T. Longaker, Thomas A. Mustoe, Mark W J Ferguson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Cutaneous scarring is an enormous medical problem with approximately 100 million patients acquiring scars each year. Scar prevention/reduction represents a significant, and largely unmet, clinical need. Research into the prophylactic modulation of scar outcome differs from research into other disease processes as the scar is not present at the start of the study; measurements of changes from baseline are impossible. Final scar morphology is influenced by many variables. A fundamental principle that should be observed in the prospective evaluation of scar prevention/reduction therapies is that, if left untreated, wounds in treatment and control groups should have healed with identical scars. Observation of this principle will allow the detection of true treatment effects. The many variables that influence scar morphology mean that the evaluation of potential pharmaceutical products for this indication favors the use of self-controlled designs in clinical trials. In this article, we review variables that affect scar morphology and recommend the self-controlled design for clinical trials aiming to establish proof of efficacy of scar prevention and reduction pharmaceuticals. With no pharmaceutical products currently licensed for this indication, this represents a new therapeutic area. The principles discussed will also have direct relevance to the wider fields of wound healing and regenerative medicine.

Original languageEnglish (US)
JournalWound Repair and Regeneration
Volume19
Issue numberSUPPL. 1
DOIs
StatePublished - Sep 2011

Fingerprint

Cicatrix
Therapeutics
Pharmaceutical Preparations
Regenerative Medicine
Controlled Clinical Trials
Wound Healing
Observation
Outcome Assessment (Health Care)
Clinical Trials
Control Groups
Skin
Wounds and Injuries

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Bush, J. A., McGrouther, D. A., Young, V. L., Herndon, D., Longaker, M. T., Mustoe, T. A., & Ferguson, M. W. J. (2011). Recommendations on clinical proof of efficacy for potential scar prevention and reduction therapies. Wound Repair and Regeneration, 19(SUPPL. 1). https://doi.org/10.1111/j.1524-475X.2010.00607.x

Recommendations on clinical proof of efficacy for potential scar prevention and reduction therapies. / Bush, James A.; McGrouther, D. Angus; Young, V. Leroy; Herndon, David; Longaker, Michael T.; Mustoe, Thomas A.; Ferguson, Mark W J.

In: Wound Repair and Regeneration, Vol. 19, No. SUPPL. 1, 09.2011.

Research output: Contribution to journalArticle

Bush, JA, McGrouther, DA, Young, VL, Herndon, D, Longaker, MT, Mustoe, TA & Ferguson, MWJ 2011, 'Recommendations on clinical proof of efficacy for potential scar prevention and reduction therapies', Wound Repair and Regeneration, vol. 19, no. SUPPL. 1. https://doi.org/10.1111/j.1524-475X.2010.00607.x
Bush, James A. ; McGrouther, D. Angus ; Young, V. Leroy ; Herndon, David ; Longaker, Michael T. ; Mustoe, Thomas A. ; Ferguson, Mark W J. / Recommendations on clinical proof of efficacy for potential scar prevention and reduction therapies. In: Wound Repair and Regeneration. 2011 ; Vol. 19, No. SUPPL. 1.
@article{5880d6b4fca146d6a680006dcd6715ca,
title = "Recommendations on clinical proof of efficacy for potential scar prevention and reduction therapies",
abstract = "Cutaneous scarring is an enormous medical problem with approximately 100 million patients acquiring scars each year. Scar prevention/reduction represents a significant, and largely unmet, clinical need. Research into the prophylactic modulation of scar outcome differs from research into other disease processes as the scar is not present at the start of the study; measurements of changes from baseline are impossible. Final scar morphology is influenced by many variables. A fundamental principle that should be observed in the prospective evaluation of scar prevention/reduction therapies is that, if left untreated, wounds in treatment and control groups should have healed with identical scars. Observation of this principle will allow the detection of true treatment effects. The many variables that influence scar morphology mean that the evaluation of potential pharmaceutical products for this indication favors the use of self-controlled designs in clinical trials. In this article, we review variables that affect scar morphology and recommend the self-controlled design for clinical trials aiming to establish proof of efficacy of scar prevention and reduction pharmaceuticals. With no pharmaceutical products currently licensed for this indication, this represents a new therapeutic area. The principles discussed will also have direct relevance to the wider fields of wound healing and regenerative medicine.",
author = "Bush, {James A.} and McGrouther, {D. Angus} and Young, {V. Leroy} and David Herndon and Longaker, {Michael T.} and Mustoe, {Thomas A.} and Ferguson, {Mark W J}",
year = "2011",
month = "9",
doi = "10.1111/j.1524-475X.2010.00607.x",
language = "English (US)",
volume = "19",
journal = "Wound Repair and Regeneration",
issn = "1067-1927",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Recommendations on clinical proof of efficacy for potential scar prevention and reduction therapies

AU - Bush, James A.

AU - McGrouther, D. Angus

AU - Young, V. Leroy

AU - Herndon, David

AU - Longaker, Michael T.

AU - Mustoe, Thomas A.

AU - Ferguson, Mark W J

PY - 2011/9

Y1 - 2011/9

N2 - Cutaneous scarring is an enormous medical problem with approximately 100 million patients acquiring scars each year. Scar prevention/reduction represents a significant, and largely unmet, clinical need. Research into the prophylactic modulation of scar outcome differs from research into other disease processes as the scar is not present at the start of the study; measurements of changes from baseline are impossible. Final scar morphology is influenced by many variables. A fundamental principle that should be observed in the prospective evaluation of scar prevention/reduction therapies is that, if left untreated, wounds in treatment and control groups should have healed with identical scars. Observation of this principle will allow the detection of true treatment effects. The many variables that influence scar morphology mean that the evaluation of potential pharmaceutical products for this indication favors the use of self-controlled designs in clinical trials. In this article, we review variables that affect scar morphology and recommend the self-controlled design for clinical trials aiming to establish proof of efficacy of scar prevention and reduction pharmaceuticals. With no pharmaceutical products currently licensed for this indication, this represents a new therapeutic area. The principles discussed will also have direct relevance to the wider fields of wound healing and regenerative medicine.

AB - Cutaneous scarring is an enormous medical problem with approximately 100 million patients acquiring scars each year. Scar prevention/reduction represents a significant, and largely unmet, clinical need. Research into the prophylactic modulation of scar outcome differs from research into other disease processes as the scar is not present at the start of the study; measurements of changes from baseline are impossible. Final scar morphology is influenced by many variables. A fundamental principle that should be observed in the prospective evaluation of scar prevention/reduction therapies is that, if left untreated, wounds in treatment and control groups should have healed with identical scars. Observation of this principle will allow the detection of true treatment effects. The many variables that influence scar morphology mean that the evaluation of potential pharmaceutical products for this indication favors the use of self-controlled designs in clinical trials. In this article, we review variables that affect scar morphology and recommend the self-controlled design for clinical trials aiming to establish proof of efficacy of scar prevention and reduction pharmaceuticals. With no pharmaceutical products currently licensed for this indication, this represents a new therapeutic area. The principles discussed will also have direct relevance to the wider fields of wound healing and regenerative medicine.

UR - http://www.scopus.com/inward/record.url?scp=79960948512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960948512&partnerID=8YFLogxK

U2 - 10.1111/j.1524-475X.2010.00607.x

DO - 10.1111/j.1524-475X.2010.00607.x

M3 - Article

VL - 19

JO - Wound Repair and Regeneration

JF - Wound Repair and Regeneration

SN - 1067-1927

IS - SUPPL. 1

ER -